Adakveo

ADAKVEO is a prescription medicine used to treat the symptoms of Sickle Cell Disease. Adakveo may be used alone or with other medications. Adakveo belongs to a class of drugs called P-Selectin Inhibitor. Safety and efficacy for Adakveo has not been established in children younger than 16 years of age. Crizanlizumab-tcma, a humanized IgG2 kappa monoclonal antibody, inhibits adhesion of sickled red blood cells by binding to P-selectin and preventing interaction with P-selectin glycoprotein ligand 1. Binding P-selectin on the surface of activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.